Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
0 hedge funds and large institutions have $0 invested in Unity Biotechnology in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 5 closing their positions.
0.17% less ownership
Funds ownership: 0.17% → 0% (-0.17%)
100% less funds holding
Funds holding: 6 → 0 (-6)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $1.68K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$831 |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$782 |
| 3 |
Steward Partners Investment Advisory
New York
|
-$56 |
| 4 |
Ameritas Investment Partners
Lincoln,
Nebraska
|
-$6 |
UBX Hedge Fund Activity: Q4 2025 in Review
0 of the 8,288 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2025, worth a combined $0 — down 100% from $1.68K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of UBX and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Osaic Holdings, exiting entirely with an estimated $831 sold.
- 0 institutional investors held Unity Biotechnology (UBX) as of Q4 2025, down from 6 in Q3 2025.
- Funds reported $0 of Unity Biotechnology stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Unity Biotechnology positions in Q4 2025 and 5 closed out, a net change of -5 holders.
- The largest Unity Biotechnology seller in Q4 2025 was Osaic Holdings, an estimated $831 sold.
Based on aggregated 13F filings for Q4 2025.